Archives
FOXM1–ERα ceRNA Network in Female Lung Adenocarcinoma: New B
2026-04-13
FOXM1–ERα ceRNA Network in Female Lung Adenocarcinoma: New Biomarker Insights
Study Background and Research Question
Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of lung cancer in women, contributing substantially to global cancer mortality [source_type: paper][source_link: https://doi.org/10.21203/rs.3.rs-3647127/v1]. Despite advances in targeted therapies, the overall survival rate for LUAD remains low, underscoring the urgent need for a deeper understanding of molecular mechanisms underlying its progression. The transcription factor FOXM1 is a recognized oncogene in multiple cancers and has been implicated in tumor growth, while estrogen receptor alpha (ERα, encoded by ESR1) is a key modulator of gene expression in hormone-dependent tissues. However, the interplay between FOXM1, ERα, and non-coding RNAs such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in female LUAD has not been fully characterized.Key Innovation from the Reference Study
Zhang et al. (2023) advance LUAD research by constructing and validating a competitive endogenous RNA (ceRNA) network involving the lncRNA DGCR5, miRNA has-miR-204-5p, FOXM1, and ERα [source_type: paper][source_link: https://doi.org/10.21203/rs.3.rs-3647127/v1]. This network provides a mechanistic bridge linking non-coding RNA regulation to protein-coding oncogenic signaling, with potential clinical implications for prognosis and therapy sensitivity.Methods and Experimental Design Insights
The study employed a multi-layered bioinformatics and experimental workflow:- Data Mining and Preprocessing: Publicly available LUAD datasets from GDC TCGA and GEO were analyzed for differential gene expression and survival correlations related to FOXM1.
- Gene Set Enrichment Analysis (GSEA): Used to identify FOXM1-associated pathways and immune infiltration profiles.
- MicroRNA Target Prediction: miRDB, miRTarBase, and TargetScan databases were integrated to predict miRNAs targeting FOXM1.
- ceRNA Network Construction: Co-expression analysis and Cytoscape visualization were deployed to map relationships among lncRNAs, miRNAs, FOXM1, and ERα.
- Tumor Mutational Burden (TMB) and Immunotherapy Sensitivity: TMB analysis was used to stratify LUAD samples and assess immune response markers.
- In Vitro Functional Assays: FOXM1 knockdown experiments assessed effects on LUAD cell proliferation and apoptosis.
Protocol Parameters
- assay | GSEA pathway enrichment | gene expression units (e.g., FPKM) | Identifies FOXM1-related pathways in LUAD | Enables functional annotation of transcriptomic changes | paper [https://doi.org/10.21203/rs.3.rs-3647127/v1]
- assay | siRNA-mediated FOXM1 knockdown | 50 nM siRNA, 48 h incubation | Assess FOXM1’s effect on cell proliferation/apoptosis | Determines functional relevance in vitro | paper [https://doi.org/10.21203/rs.3.rs-3647127/v1]
- assay | TMB stratification | nonsynonymous mutations per Mb | Predicts immunotherapy sensitivity | Stratifies patient response groups | paper [https://doi.org/10.21203/rs.3.rs-3647127/v1]
- workflow_recommendation | Selective ERα agonist (e.g., PPT) in LUAD cell models | 1–10 μM, 24–72 h | Dissects ERα-mediated gene expression in vitro | Based on internal optimizations and literature | workflow_recommendation
Core Findings and Why They Matter
Key results from Zhang et al. include:- Elevated FOXM1 Expression: LUAD tissues displayed higher FOXM1 levels than normal lung, correlating with poor patient prognosis [source_type: paper][source_link: https://doi.org/10.21203/rs.3.rs-3647127/v1].
- FOXM1's Biological Impact: Knockdown of FOXM1 suppressed LUAD cell proliferation and induced apoptosis, validating its oncogenic role.
- ceRNA Network Elucidation: The DGCR5—has-miR-204-5p—FOXM1—ERα axis was mapped, revealing that has-miR-204-5p directly targets FOXM1, but DGCR5 does not act as a target lncRNA for this miRNA. Physical interactions between FOXM1 and estrogen receptors were experimentally supported.
- Immunotherapy Sensitivity: LUAD cases with lower FOXM1 expression were more responsive to immune checkpoint inhibitors (anti-PD1, anti-CTLA4), as indicated by TMB and immune infiltration analysis.
Comparison with Existing Internal Articles
Several internal resources have previously explored the utility of ERα-selective agonists, such as PPT (Propyl Pyrazole Triol), in dissecting estrogen receptor signaling and ceRNA networks in cancer. For example, “PPT (Propyl Pyrazole Triol): Advancing ERα-Selective Ligand Research” contextualizes PPT’s role in exploring ceRNA–ERα crosstalk in LUAD, offering practical guidance for leveraging selective agonists in mechanistic studies. Similarly, “PPT: Precision Tool for Selective Estrogen Receptor Alpha Signaling” discusses optimized workflows for FOXM1–ERα network analysis, directly building on concepts from Zhang et al. [source_type: workflow_recommendation][source_link: https://lprolinecatalog.com/index.php?g=Wap&m=Article&a=detail&id=86]. These articles align with the reference study’s evidence and provide actionable directions for implementing selective ERα agonists in LUAD models.Limitations and Transferability
While the study robustly integrates bioinformatics and cell-based validation, several limitations warrant consideration:- The ceRNA network was primarily validated in vitro, and in vivo relevance in clinical LUAD samples requires further confirmation.
- The study focuses on female LUAD; applicability to male patients or other lung cancer subtypes remains to be established.
- Functional dissection of ERα-mediated gene expression was inferred but not directly manipulated with selective agonists such as PPT in these experiments.